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The Regulation of Vascular Endothelial Growth Factor
by Hypoxia and Prostaglandin F2 during Human
Endometrial Repair
Jacqueline A. Maybin, Nikhil Hirani, Pamela Brown, Henry N. Jabbour,
and Hilary O. D. Critchley
Centre for Reproductive Biology (J.A.M., H.O.D.C.), University of Edinburgh, Edinburgh EH16 4TJ,
United Kingdom; and Centre for Inflammation Research (N.H.) and Human Reproductive Sciences Unit
(P.B., H.N.J.), Medical Research Council, Edinburgh EH 16 4TJ, United Kingdom
Context: The human endometrium has an exceptional capacity for repeated repair after menses,
but its regulation remains undefined. Premenstrually, progesterone levels fall and prostaglandin
(PG) F2 synthesis increases, causing spiral arteriole constriction. We hypothesized that progester-
one withdrawal, PGF2, and hypoxia increase vascular endothelial growth factor (VEGF), an en-
dometrial repair factor.
Design and Results: Endometrial biopsies were collected (n  47) with ethical approval and con-
sent. VEGF mRNA, quantified by quantitative RT-PCR, was increased during menstruation (P 
0.01).VEGF proteinwasmaximally secreted from proliferative endometrial explants. Treatment of
an endometrial epithelial cell line and primary human endometrial stromal cells with 100 nM PGF2
orhypoxia (0.5%O2) resulted in significant increases inVEGFmRNAandprotein.VEGFwasmaximal
when cells were cotreated with PGF2 and hypoxia simultaneously (P  0.05–0.001). Secretory-
phaseendometrial explantsalso showedan increase inVEGFwithcotreatment (P0.05).However,
proliferative-phase explants showed no increase in VEGF on treatmentwith PGF2 and/or hypoxia.
Proliferative tissuewas induced to increaseVEGFmRNAexpressionwhenexposed toprogesterone
and itswithdrawal in vitrobut only in the presence of hypoxia and PG.Hypoxia-inducible factor-1
(HIF-1) silencing with RNA interference suppressed hypoxia-induced VEGF expression in endo-
metrial cells but did not alter PGF2-induced VEGF expression.
Conclusions: Endometrial VEGF is increased at the time of endometrial repair. Progesterone with-
drawal, PGF2, and hypoxia are necessary for this perimenstrual VEGF expression. Hypoxia acts via
HIF-1 to increase VEGF, whereas PGF2 acts in a HIF-1-independent manner. Hence, two pathways
regulate theexpressionofVEGFduringendometrial repair. (J Clin EndocrinolMetab96: 2475–2483, 2011)
The human endometrium has a remarkable capacity forscar-free repair after the inflammatory process of
menstruation (1, 2). Currently, our understanding of this
process is limited, with the factors involved and their reg-
ulation remaining elusive.Delayed repairmay result in the
common gynecological complaint of prolonged, heavy
menstrual bleeding (HMB).One in threewomenconsiders
theirmenstruation excessive, rising to one in two asmeno-
pause approaches (3). Although medical treatment op-
tions are available, a significant proportion of women re-
quire surgery due to treatment failure (4). It is essential to
fully understand the endometrial repair processes to im-
prove medical treatments and avoid surgical risks. Fur-
thermore, elucidating the mechanisms of efficient endo-
metrial repair may have wider implications, identifying
novel treatment targets in tissue sites where persistent in-
flammation and scarring are problematic.
Angiogenesis is mandatory for efficient repair and re-
modeling. Vascular endothelial growth factor (VEGF) is a
key factor in physiological and pathological angiogenesis
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(5–7). This secreted protein stimulates endothelial cell
proliferation and migration (5, 8, 9). It acts through two
receptors, VEGFR1 and VEGFR2, both expressed in the
human endometrium (10, 11). In the primate, VEGF is
essential for neoangiogenesis during postmenstrual repair
(9). Aberrant endometrial expression of VEGF has been
demonstrated in women with HMB, with lower levels in
these women compared with normal controls (12). How-
ever, the regulation of VEGF during endometrial repair
remains undefined.
As the corpus luteum regresses at the end of the men-
strual cycle, progesterone levels fall. This triggers the re-
lease of inflammatory mediators within the endometrium
that initiate menstruation (1). Although endometrial re-
pair was traditionally considered to be regulated by es-
trogen, research in the mouse model of simulated men-
struation has suggested itmay be an estrogen-independent
event (13). We propose that progesterone withdrawal si-
multaneously initiatesmenstruation and repair.After pro-
gesterone withdrawal, there is an increase in endometrial
prostaglandin (PG) synthesis, namely PGE2 and PGF2 (1,
14). PGF2 is a potent vasoconstrictor and, alongside
other factors, acts on the spiral arterioles to cause intense
vasoconstriction premenstrually (15). The role of PGE2
during endometrial repair has not been fully defined. Spi-
ral arteriole vasoconstriction is likely to cause an episode
of transient, local hypoxia in the uppermost endometrial
zones. Classic experiments in the rhesus monkey first sug-
gested the presence of perimenstrual hypoxia (15). More
recently, use of amarker of cell hypoxia, pimonidazole, in
mice has confirmedoxygen levels below10mmHgduring
menstruation (9). Hypoxia-inducible factor 1 (HIF-1) is a
transcription factor known to regulate the cellular re-
sponse to hypoxia. In hypoxic conditions the two subunits
(HIF-1 and HIF-1) dimerize and initiate transcription
of target genes, including factors involved in angiogenesis
(16–18). HIF has been identified in the human endome-
trium during the late secretory andmenstrual phases (19).
We hypothesized that 1) VEGF is increased during
menstruation when endometrial repair is initiated, and 2)
this increase is regulated by progesterone withdrawal, PG
synthesis, andhypoxic conditions.Hereinwedemonstrate
endometrial VEGF expression ismaximal during themen-
strual phase. In vitro endometrial cell studies revealed that
hypoxia, PGE2, and PGF2 induce VEGF expression. Ex
vivo endometrial explant studies showed that VEGF ex-
pression was increased by hypoxia and PG only in tissue
from the secretory phase. However, when proliferative
explants were exposed to progesterone in vitro followed
by progesteronewithdrawal in hypoxic conditions, VEGF
expression was significantly increased. Furthermore, we
show that hypoxia regulates VEGF expression via HIF-
1, whereas PGF2 induces VEGF expression indepen-
dently of HIF-1.
Materials and Methods
Human endometrial tissue collection
Endometrial biopsies (n  47) were collected with a suction
curette (Pipelle, Laboratorie CCD, Paris, France) from women
(median age 42 yr, range 22–50) attending the gynecological
outpatient department. All reported regular menstrual cycles
(21–35 d) and no exogenous hormone exposure for 3 months
before biopsy. Women with large fibroids (3 cm) or endome-
triosis were excluded. Tissue was divided and 1) placed in RNA-
later, RNA stabilization solution [Ambion (Europe) Ltd., War-
rington, UK], 2) fixed in neutral buffered formalin for wax
embedding, and 3) placed in PBS for in vitro culture. Biopsies
were consistent for 1) histological dating [criteria of Noyes et al.
(20)], 2) reported last menstrual period, and 3) serum proges-
terone and estradiol concentrations at time of biopsy (Table 1).
Seven women providing a biopsy in the proliferative, early/mid-
secretory phase returned for an additional biopsy 3–6 months
after insertionof the levonorgestrel-releasing intrauterine system
(LNG-IUS) for management of heavy menstrual bleeding. Writ-
ten consent was obtained fromparticipants and ethical approval
granted from the Lothian Research Ethics Committee.
Immunohistochemistry
The 3-m paraffin sections were dewaxed and rehydrated.
Antigen retrieval was undertaken by microwaving sections in a
high-pH heat-induced antigen retrieval buffer (pH 9.0). Endog-
enous peroxidase activity was blocked by 3% hydrogen perox-
ide. Sections were sequentially incubated in avidin and biotin
(Vector Laboratories, Peterborough, UK) and protein block
(Dako, Cambridge, UK). Mouse monoclonal anti-VEGF anti-
body (12.4 g/ml; R&D Systems, Abingdon, UK) was applied
overnight at 4 C. Negative controls were incubated with an
equivalent concentration of mouse IgG2B. Biotinylated rabbit
antimouse secondary antibodywasused at 1:200.Avidin-biotin-
peroxidase complex (ABC-Elite; Vector) was applied for 30min
and liquiddiaminobenzidinekit (ZymedLaboratories, SanFran-
cisco, CA) used for detection. The reaction was stopped with
distilled water and sections counterstained with hematoxylin,
dehydrated, and mounted with Pertex (Cellpath plc, Hemel
Hempstead, UK).
TABLE 1. Serum estradiol and progesterone levels at
the time of endometrial biopsy
Number
Mean estradiol
levels pmol/liter
(range)
Mean progesterone
levels nmol/liter
(range)
Menstrual 8 197.25 (55–514) 3.71 (1.24–10.59)a
Proliferative 14 476.18 (79–1105) 2.68 (0.97–7.1)a
Early secretory 9 497.50 (289–841) 59.60 (23.2–112.91)
Mid secretory 10 638.00 (242–1949) 64.30 (25.47–114.53)
Late secretory 6 318.22 (59.09–819) 8.22 (1.06–16.95)a
a Progesterone levels are significantly lower than in the early-mid
secretory phases (P  0.001).
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Culture of endometrial explants
All explants were cultured on sterile capillary bedding just
covered with serum-free RPMI 1640medium tominimize tissue
hypoxia. Four experiments were carried out.
1) Proliferative (n3) and secretory (n3–6) phase biopsies
were divided into four equal explants and treatedwith vehicle or
100 nM PGF2 and placed in normoxic conditions (21%O2, 5%
CO2, 37 C) or in a sealed hypoxic chamber (0.5%O2, 5%CO2,
37 C; Coy Laboratory Products, Grass Lake, MI) for 24 h.
2) Proliferative biopsies (n  4) were divided into eight ex-
plants. All were treatedwith 1Mmedroxyprogesterone acetate
(MPA) for 24 h. Explantswere then treated for 48 hwith 1) 1M
MPA plus vehicle, 2) 1 M MPA plus 8.4 M indomethacin [a
cyclooxygenase (COX) inhibitor], 3) 1MMPAplus 1Mmife-
pristone (RU486, aprogesterone receptor antagonist), or4)1M
MPA plus 1 M mifepristone plus 8.4 M indomethacin. This
48-h incubation was carried out in both normoxic and hypoxic
conditions.
3) Four additional endometrial biopsies were divided into
four explants and treated with progesterone (1 M) for 24 h
before washing with PBS followed by treatment with progester-
one or vehicle in normoxic and hypoxic conditions for 48 h.
4)Endometrial tissue fromacross themenstrual cycle (n22)
was weighed and cultured for 24 h in 1 ml RPMI 1640 at 37 C
in normoxia and the culture supernatant analyzed by ELISA.
Culture of endometrial cells
Human Ishikawa endometrial adenocarcinoma cells (Euro-
pean Collection of Cell Cultures, Centre for Applied Microbi-
ology, Wiltshire, UK) were stably transfected with the PGF2
receptor (FPS cells) (21). Primary human endometrial stromal
(HES) cells were isolated from endometrial tissue (n  3) by
enzymatic digestion as previously described (22).
To determine the effect of PGF2 and/or hypoxic conditions
on VEGF expression, approximately 4  105 FPS or HES cells
were seeded in six-well plates. The following day, cells were
incubated in serum-free culture medium containing 8.4 M in-
domethacin (COX enzyme inhibitor) for at least 16 h. Cells were
then treated with vehicle or 100 nM PGF2 and placed in nor-
moxia (21% O2, 5% CO2, 37 C) or a sealed hypoxic chamber
(0.5% O2, 5% CO2, 37 C) for 2, 4, 8, 24, and 48 h.
Two different 19-nucleotide short hairpin RNA (shRNA) se-
quences derived from human HIF-1 mRNA (U22431; bp
1470–1489 and bp 2192–2211) and a scrambled control oligo-
nucleotide were used and have been described previously (23,
24). These sequences are termed HIF-1/shRNA1470 and HIF-
1/shRNA2192. Cells were transiently transfected with the
shRNA sequences using a lentiviral vector at MOI 10 for 24 h.
Cells were incubated in serum-free medium overnight before
placement in the hypoxic chamber for 8 h. Cells were washed
with PBS and harvested, and RNA or protein was extracted for
PCR or Western blot analysis.
Quantitative RT-PCR
Expression of VEGF in endometrial tissue and cells was de-
termined by quantitative RT-PCR (TaqMan) analysis. Total
RNAfromcells andendometrial biopsieswas extractedusing the
RNeasyMiniKit (QIAGENLtd., Sussex,UK) according toman-
ufacturer’s instructions. Samples were treated for DNA contam-
ination by DNA digestion during RNA purification. RNA sam-
ples were reverse transcribed using MgCl2 (5.5 mM), deoxy (d)
nucleotide triphosphates (0.5 mM each) random hexamers (2.5
M), ribonuclease inhibitor (0.4 U/l), and multiscribe reverse
transcriptase (1.25 U/l; all from PE Biosystems, Warrington,
UK); 200–400 ng of RNA was added. A tube with no reverse
transcriptase and another tube with water were included as con-
trols. To measure cDNA expression, a reaction mix was pre-
pared containing TaqMan buffer (5.5mMMgCl2, 200MdATP
200 M dCTP, 200 M dGTP, 400 M deoxyuridine triphos-
phate), ribosomal 18S primers/probe (Applied Biosystems,War-
rington, UK) and specific forward and reverse primers and
probes: VEGF forward primer 5-TACCTCCACCATGC-
CAAGT-3, reverse primer 5-TAGCTGCGCTGATAGACAT-
3, and probe 5-ACTTCGTGATGATTCTGCC-3; lamin A/C
forward primer 5-AGCAAAGTGCGTGAGGAGTT-3, re-
verse primer 5-AGGTCACCCTCCTTCTTGGT-3, and Uni-
versal probe library no. 17.A0.4-l volume of cDNAwas added
for each PCR. Negative controls (water instead of cDNA) were
included in each run. PCRwas carried out using ABI Prism 7900
(Applied Biosystems). Samples were analyzed in triplicate using
Sequence Detector version 2.3 (PE Biosystems). Expression of
target mRNA was normalized to RNA loading for each sample
using the 18S rRNA as an internal standard. There was no sig-
nificant change in 18S rRNA expression between normoxic and
hypoxic conditions.
Nuclear protein extraction
Cytoplasmic proteins were extracted from endometrial epi-
thelial (FPS) cells with a cytoplasmic protein lysis buffer [10 mM
HEPES (pH 7.8), 10 nM KCl, 2 mMMgCl2, 1 mM dithiothreitol,
0.1 mM EDTA, 10% Nonidet P-40] containing protease inhib-
itors (Roche Diagnostics Ltd., Lewes, UK). The membrane frac-
tion was pelleted by centrifugation at 13,000 rpm for 1 min at 4
C. Cytoplasmic fraction supernatant was removed and stored at
80C.Thenuclear fractionwas extractedwithanuclearprotein
lysis buffer [50 mMHEPES (pH 7.8), 50 nM KCl, 300 mMNaCl,
0.1 mM EDTA, 1 mM dithiothreitol, 10% glycerol] containing
protease inhibitors (Roche) followed by agitation for 20 min at
4 C and centrifugation at 13,000 rpm for 5 min at 4 C. Nuclear
fraction supernatant was stored at 80 C. Protein content was
determined using protein assay kits (Bio-Rad, Hemel Hemp-
stead, UK).
HIF-1 Western blot analysis
A total of 15 g nuclear protein from FPS cells was resus-
pended in a2:1 ratiowithLaemmli buffer [125mMTris-HCl (pH
6.8), 4% sodium dodecyl sulfate, 5% 2-mercaptoethanol, 20%
glycerol, and0.05%bromophenol blue] anddenatured for5min
at 90 C. Proteins were separated on 4–12% Bis-Tris gels (Nu-
PAGE Novex; Invitrogen, Carlsbad, CA) and transferred onto
polyvinylidene difluoridemembranes (Millipore,Watford, UK).
Membranes were blocked overnight before incubation with pri-
mary antibodies for 2h at room temperature:mousemonoclonal
HIF-1 antibody (BD Biosciences, Oxford, UK) at 1:250 and
rabbit polyclonal to-actin (Abcam,Cambridge,UK) at 1:5000.
After washing, the membrane was incubated with horseradish
peroxidase-conjugated goat antimouse IgG (Dako) or horserad-
ish peroxidase-conjugated mouse antirabbit IgG (Sigma Aldrich
Company Ltd. Dorset, UK) at 1:20000. Chemiluminescent
horseradish peroxidase substrate (Immobilon Western; Milli-
pore Corp., Billerica, MA) was used for detection according to
manufacturer’s instructions.
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VEGF ELISA
Levels of VEGF in culture supernatants were determined in
triplicate samples using a commercially available ELISA kit (Pe-
proTech, London, UK), according to manufacturer’s instruc-
tions. Protein values in explant experimentswere normalized for
tissue weight.
Statistics
For cell and tissue culture,mRNAresults are expressedas fold
increase, where relative expression of mRNA on treatment was
divided by the relative expression after vehicle treatment. Data
are presented as mean 	 SEM, and significance of raw data was
determined using one-wayANOVAwithTukey’smultiple-com-
parison test. For endometrium from across the menstrual cycle,
mRNA results are expressed as quantity relative to a compara-
tor, a sample of RNA from the liver. Significant differences in
mRNA and protein were determined using Kruskal-Wallis non-
parametric test with Dunn’s multiple-comparison posttest
(Prism version 4.02; GraphPad Software, Inc., San Diego, CA).
Results
VEGF levels are increased at menstruation
Endometrial VEGF mRNA expression varied signifi-
cantly across the menstrual cycle (P  0.0005) (Fig. 1A).
Maximal expression was observed in menstrual endome-
trium, when levels were significantly higher than in the
proliferative (P  0.05) and early secretory (P  0.01)
phases. VEGF protein secreted by endometrial explants
from across the menstrual cycle was measured by ELISA.
VEGF protein secretion was significantly greater from
proliferative explants compared with late secretory endo-
metrium (P  0.05) (Fig. 1B). Immunolocalization of
VEGF protein in menstrual endometrium (Fig. 1C)
showed positive cytoplasmic staining in the surface epi-
thelial cells (SE), glandular epithelial cells (GE), stromal
compartment (St), and perivascular cells (arrows).
Regulation of VEGF in endometrial epithelial cells
An endometrial epithelial cell line stably transfected
with the PGF2 receptor (FPS cells) was used to investigate
the regulation of VEGF expression. This cell line was used
because primary endometrial epithelial cells have a limited
capacity for proliferation in culture but do contain this PG
receptor in vivo (25, 26). FPS cells treated with 100 nM
PGF2or hypoxia showeda trend toward increasedVEGF
mRNA expression; this increase reached significance
when both factorswere present simultaneously (P 0.05)
(Fig. 2A). VEGF secreted protein levels
were significantly increased in the cul-
ture supernatants from FPS cells
treated for 24 h with PGF2, hypoxia,
or both (P  0.001) (Fig. 2B).
Regulation of VEGF in primary
HES cells
Treatment of HES cells with 100 nM
PGF2 in normoxia had no effect on
VEGF mRNA expression (Fig. 2C).
However, incubation of HES cells in
hypoxic conditions for 24 h revealed a
significant increase in VEGF (P 
0.01). Simultaneous treatment of HES
cells with PGF2 and hypoxia also sig-
nificantly elevated VEGF mRNA ex-
pression (P  0.01) (Fig. 2C). VEGF
secreted protein levels were signifi-
cantly increased when HES cells were
incubated for 24 h with PGF2 and
hypoxia vs. vehicle-treated cells in nor-
moxia (P  0.05) (Fig. 2D).
Regulation of VEGF levels in
human endometrial tissue
explants
Proliferative endometrial explants
treated with 100 nM PGF2 in nor-
moxia or hypoxia showed no signifi-
FIG. 1. Endometrial VEGF is increased during menstruation. A, VEGF mRNA expression in
endometrial biopsies from across the menstrual cycle; B, VEGF secreted protein from
endometrial explants collected at each menstrual cycle stage; C, immunolocalization of VEGF
in menstrual endometrium; D, menstrual negative control tissue. ES, Early-secretory; GE,
glandular epithelial cells; KW, Kruskal Wallis; LS, late-secretory; M, menstrual; MS,
mid-secretory; P, proliferative; SE, surface epithelial cells; St, stromal cell compartment. *, P 
0.05; ***, P  0.001. Arrows indicate perivascular cells. Scale bar, 50 m.
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cant changes in VEGF mRNA expression (Fig. 3A). In
contrast, explants from the secretory phase displayed sig-
nificant increases in VEGFmRNA expression after cotreat-
ment with PGF2 and hypoxia (P  0.05) (Fig. 3B). This
variedresponsebetweenendometriumfromtheproliferative
and secretory phase suggests previous progesterone expo-
sure may influence the ability of tissue to respond.
The effect of progesterone, and its withdrawal, on
VEGF expression
To test the hypothesis that previous progesterone ex-
posure is necessary for VEGF induction, we used ex vivo
models of progesterone withdrawal. Proliferative endo-
metrial biopsiesweredivided into eight equal explants and
pretreated for 24 h with progestin (MPA). Explants were
then cotreatedwithMPAplus 1) vehicle; 2) indomethacin,
a COX inhibitor; 3) a progesterone receptor antagonist
(RU486); or 4)RU486and indomethacin for 48h.Exvivo
progesterone antagonism in normoxia did not show sig-
nificant up-regulation of VEGFmRNA (Fig. 3C). In vivo,
progesterone withdrawal is followed by hypoxia due to
spiral arteriole vasoconstriction. When we antagonized
progesterone in hypoxic conditions to mimic the in vivo
scenario more accurately, there was a significant increase
in VEGF mRNA expression (Fig. 3C). This increase was
abrogated by cotreatment with indomethacin to suppress
PG production, suggesting that both
hypoxia and PG are necessary to in-
crease endometrial VEGF expression
after progesterone withdrawal. Be-
cause synthetic agents such as MPA
andRU486mayhaveoff-target effects,
additional endometrial biopsies were
treatedwithprogesterone for24hbefore
treatmentwithvehicleormaintenance in
progesterone. Again, only explants ex-
posed to progesteronewithdrawal in hy-
poxic conditions showedasignificant in-
crease in VEGF expression (P  0.05)
(Fig. 3D).
We examined paired endometrial bi-
opsies collected from the same woman
before and 3–6 months after LNG-IUS
insertion (n  7). The LNG-IUS is
known to down-regulate the endome-
trial progesterone receptor (27) andmay
represent an in vivomodel of progester-
one deprivation. We identified a signifi-
cant up-regulation of VEGF mRNA ex-
pression in endometrium collected after
LNG-IUS insertion when compared
with preinsertion biopsies (P  0.05)
(Fig. 3D).
The contribution of HIF-1 to the regulation of
endometrial VEGF
To assess the contribution of the transcription factor
HIF-1 to endometrial VEGF expression, we transfected
FPS cells with two different shRNA sequences against
HIF-1 (HIF-1/sh1470 and HIF-1/sh2192) and con-
firmed HIF-1 silencing by Western blot analysis (Fig.
4A). Transfection with either sequence reduced HIF-1
protein levels in response to hypoxia, whereas a control
scrambled sequence had no such effect (Fig. 4A). Speci-
ficity of the shRNA sequences was examined by measure-
ment of lamin A/C mRNA levels, which revealed no sig-
nificant changes upon transfection with any construct
(Fig. 4B). HIF-1 silencing had no significant impact on
PGF2-induced VEGF mRNA expression (Fig. 4C). In
contrast, hypoxic induction of VEGF was significantly
lower in cells where HIF-1was silenced when compared
with untransfected cells or cells transfected with HIF-1/
shSCR (P  0.05) (Fig. 4D).
Discussion
The novel data presented herein detail the requirement for
progesterone withdrawal, hypoxic conditions, and PG
FIG. 2. The regulation of VEGF in human endometrial cells. A, VEGF mRNA expression in a
human endometrial epithelial cell line (FPS cells) treated with vehicle, 100 nM PGF2, hypoxia,
or both hypoxia and PGF2 for 24 h; B, VEGF secreted protein levels in the culture
supernatants from FPS cells; C, VEGF mRNA expression in primary HES cells treated with
vehicle, 100 nM PGF2, hypoxia, or both hypoxia and PGF2 for 24 h; D, VEGF secreted protein
levels in the culture supernatants from these HES cells. All results are from three separate
experiments; HES cells were isolated from three different women. Normoxia  21% O2;
hypoxia  0.5% O2. *, P  0.05; **, P  0.01; ***, P  0.001.
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production to increase endometrial VEGF during men-
struation.We confirm that hypoxia increases endometrial
VEGF production and describe, for the first time, its de-
pendence upon endometrial HIF-1. In addition, we re-
veal a novel PGF2-mediated increase in endometrial
VEGF expression that is independent of HIF-1.
Electron microscopy of the human endometrium has
shown that repair commencesond2of themenstrual cycle
(28). Because repair is initiated at menstruation, the fac-
tors involved must be up-regulated during
this phase. Herein we have shown signifi-
cant up-regulation of endometrial VEGF
mRNA and protein during menstruation.
This is consistent with findings in the rhe-
sus macaque, where heightened expres-
sion of VEGF was present in the newly
formed surface epithelium and stroma
duringpostmenstrual repair (29). Previous
immunohistochemical and in situ hybrid-
ization studies have also shown increased
VEGF expression in the human endome-
triumduringmenstruation (30, 31).VEGF
is a potent angiogenic factor that stimu-
lates endothelial cell proliferation and mi-
gration (5). A recent study examining the
decidualized mouse uterus and rhesus ma-
caque endometrium found that VEGF
blockade with VEGF-Trap (a VEGF blocker)
completely inhibited neovascularization
and reepithelialization during endometrial
repair (9). Interestingly, a previous study of
thehumanendometriumfoundsignificantly
decreased VEGF mRNA and protein levels
in women with HMBwhen compared with
controls (12). Therefore, delineation of the
regulation of this important repair factor
may provide novel therapeutic targets
for HMB.
Herein we have shown that progester-
onewithdrawal, hypoxia, and PGproduc-
tion are required to increaseVEGF expres-
sion in endometrial explants. An elegant
study of ovariectomized, artificially cy-
clingmacaques reported an estrogen-inde-
pendent elevation in stromal VEGF imme-
diately after progesterone withdrawal
(29). An estrogen-dependent increase in
VEGF occurred subsequently, during the
proliferative phase, suggesting estradiol is
involved in remodeling but not in the ini-
tial phase of endometrial repair. Our ex
vivo models further delineate events after
progesteronewithdrawal in the human en-
dometrium. Progesterone withdrawal appears necessary,
but alone is not sufficient, to induce endometrial VEGF.
Downstream hypoxia and PG production are also re-
quired for endometrial VEGF expression. Previous studies
have shown hypoxic induction of VEGF in isolated endo-
metrial stromal and epithelial cells (32), but to our knowl-
edge, this is the first time hypoxia has been shown to be
involved in VEGF induction in endometrial tissue. PGs
FIG. 3. The effect of progesterone withdrawal, prostaglandins, and hypoxia on VEGF
expression in the endometrium. A, VEGF mRNA expression in endometrial explants from
the proliferative phase treated with vehicle, 100 nM PGF2, hypoxia, or both hypoxia and
PGF2 (n  3) for 24 h. B, VEGF mRNA expression in secretory endometrial explants
treated with vehicle, 100 nM PGF2, hypoxia, or both hypoxia and PGF2 (n  3) for 24 h.
C, Proliferative-phase explants (n  4) were pretreated with1 M MPA and then 1)
maintained in 1 M MPA (P), 2) cotreated with 1 M MPA and 1 M RU486, a
progesterone receptor antagonist (P
RU486), or 3) cotreated with 1 M MPA, 1 M
RU486, and 8.4 M indomethacin, a COX enzyme inhibitor (P
RU486
IndoM). Identical
treatments were incubated in either normoxia (21% O2) or hypoxia (0.5% O2). D,
Endometrial explants pretreated with 1 M progesterone followed by maintenance in
progesterone (P) or incubation with vehicle to induce progesterone withdrawal (Pw/d) in
normoxia and hypoxia. E, Insertion of the LNG-IUS (IUS), with consequent local reduction
in progesterone receptor expression analogous to local progesterone withdrawal, resulted
in a significant increase in VEGF mRNA expression; note logarithmic scale on y-axis.
Normoxia  21% O2; hypoxia  0.5% O2. *, P  0.05; **, P  0.01.
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have previously been shown to increase VEGF expression
in cancer cells (16, 33), but we demonstrate a potential
physiological role in the human endometrium.
We examined endometrial biopsies from women col-
lected before and 3–6 months after LNG-IUS insertion for
treatment of HMB. LNG-IUS insertion dramatically down-
regulates endometrial progesterone receptors, providing an
in vivomodel of local endometrial progesterone deprivation
(27, 34). In addition, progestogen exposure has been shown
to reduce endometrial perfusion and profoundly decrease
vasomotion (35).Thismay lead to endometrial hypoxia.En-
dometrial samples taken after LNG-IUS insertion showed a
significant increase in VEGF mRNA expression. Because
normal endometrial architecture ismaintained in thismodel,
our findings support the role of progesterone withdrawal
and downstream hypoxia in the up-regulation of endome-
trialVEGF.Furthermore, theLNG-IUS iswell establishedas
a treatment for HMB, and this stimulation of VEGF pro-
duction may contribute to its efficacy.
For the first time, we have demonstrated that hypoxic
induction of VEGF in endometrial cells is mediated via
HIF-1. HIF-1 is a heterodimeric factor. TheHIF-1 sub-
unit undergoes proteasomal degradation in normoxia,
whereas HIF-1 is constitutively expressed. In hypoxic
conditions,HIF-1 bindswithHIF-1, translocates to the
nucleus, and increases the transcription of target genes, in-
cluding those involved in angiogenesis (16, 17, 36). HIF-1
hasbeen showntobe induced in late secretoryandmenstrual
endometrium (19). A hypoxic response element is present in
the VEGF promoter region, and HIF-1 has been shown to
regulate VEGF expression in hypoxic Hep3B cells (37). In
contrast, HIF-1-independent hypoxic regulation of VEGF
has been described in colon cancer cells (23). Our results
suggest HIF-1 is involved in hypoxia-induced increases in
endometrial VEGF production at menstruation but that
PGF2 acts independently of HIF to increase VEGF. A pre-
vious study of endometrial adenocarcinoma explants and
cells showedthatPGF2activates theERK1/2signalingpath-
way inanepidermalgrowth factor receptor-dependentman-
ner to increase VEGF promoter activity (33). Additional
studies are required to determine whether a similar mecha-
nism of action is present in normal endometrial tissue.
In conclusion, our data generated from 1) in vitro cell
studies, 2) ex vivo explant culture, and 3) an in vivomodel
FIG. 4. HIF-1 silencing in FPS cells prevents hypoxic induction of VEGF- but not PGF2-mediated increases. A, Confirmation of HIF-1 protein
knockdown by Western blot with transfection of two short hairpin sequences against HIF-1 (HIF-1/sh1470 and HIF-1/sh2192), compared with a
scrambled sequence (shSCR) or untransfected cells after 8 h in hypoxic conditions (0.5% O2); B, specificity of the knockdown was confirmed by
examining lamin A/C mRNA expression, which showed no significant changes with transfection of any construct; C, silencing of HIF-1 had no
significant effect on PGF2-mediated VEGF expression; D, cells transfected with shRNA against HIF-1 had a significantly abrogated response to
hypoxic stimulation, with low levels of VEGF expression compared with untransfected cells or those transfected with a scrambled sequence.
*, P  0.05; **, P  0.01; ns, nonsignificant.
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of progesterone deprivation indicate that progesterone
withdrawal, hypoxia, and PGF2 are involved in produc-
tion of VEGF for endometrial repair. There is evidence
that women with HMB have decreased levels of VEGF
during menstruation (12). These women are also known
tohave aberrant PGproduction and signaling (38, 39) and
may therefore have suboptimal initiation of repair leading
to heavy, prolonged bleeding. Additional studies are re-
quired to determine whether there is a defective hypoxic
response in womenwith HMB, resulting in less menstrual
expression of VEGF. Delineation of the physiological reg-
ulation of endometrial repair may lead to novel, effica-
cious treatments for these women.
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